While knowledge gaps remain regarding the potential risks of nanotechnologies, the European Commission again expressed confidence that existing EU regulation can be applied to this emerging sector, stressing that the cha...
Konarka Technologies, Inc., an innovator in development and commercialization of Power Plastic®, a material that converts light to energy, today announced the company has opened the largest roll-to-roll flexible thin...
Sigma-Aldrich is pleased to announce that it has signed an exclusive licensing agreement with the University of Illinois at Urbana-Champaign allowing Sigma-Aldrich to offer research quantities of powerful new boronic acid surrogates for use in Suzuki-Miyaura coupling to researchers worldwide. Under the terms of the agreement, Sigma-Aldrich can also satisfy commercial-scale requests for these surrogates from its manufacturing customers.
Microfluidics, a division of Microfluidics International Corporation, announces the availability of several new services designed to enhance customer success and assist in customer innovation. These new services build on...
Paragon Intellectual Properties, LLC, today announced that it has restructured the company, moving from a limited liability company with seven subsidiaries to a single C-corporation to form Nexeon MedSystems, Inc. This r...
From petroleum to food and beverage to pharmaceuticals, most industries use mechanical pumps, and all these pumps rely on seals to reduce leaks and maintenance costs. Argonne researchers, along with industry partners, have developed a new, efficient and cost-effective alternative to conventional seals.
MDRNA, Inc. announced today that it has advanced its RNAi pipeline with the selection of a Lead Candidate in its hypercholesterolemia program targeting Apolipoprotein B (ApoB). The compound, designated MDR-04227, was dev...
Applied Nanotech Holdings, Inc. today announced that the third phase of its research project with a leading industrial chemical products company in Japan, announced on September 29, 2008, has been expanded and the previo...
Particle Sciences announced today that it has sold T-COTE, its proprietary line of microfine titanium dioxide, to Sensient. With the sale, Sensient assumes all marketing and sales responsibilities and acquires the associ...
The National Comprehensive Cancer Network (NCCN), Abraxis BioScienc, and AstraZeneca today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.